Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$11.25 USD
+0.09 (0.81%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.28 +0.03 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Oric Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 |
Depreciation/Amortization & Depletion | -5.14 | -0.08 | 2.25 | 1.27 | 1.03 |
Net Change from Assets/Liabilities | 4.90 | -0.45 | 4.07 | 2.05 | 1.22 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.25 | 14.50 | 12.86 | 25.12 | 1.10 |
Net Cash From Operating Activities | -85.69 | -75.14 | -59.54 | -45.27 | -23.53 |
Property & Equipment | -0.85 | -2.08 | -0.94 | -0.67 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | -0.77 |
Investments | -42.55 | -107.17 | 159.37 | -215.49 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 |
Net Cash from Investing Activities | -43.40 | -109.25 | 158.44 | -215.96 | -0.77 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 85.88 | 25.62 | 50.99 | 271.75 | 70.92 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.23 | -0.40 | -1.85 | -21.24 | -0.10 |
Net Cash from Financing Activities | 85.66 | 25.23 | 49.13 | 250.51 | 70.82 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -43.43 | -159.17 | 148.03 | -10.71 | 46.52 |
Cash at Beginning of Period | 67.31 | 226.47 | 78.45 | 89.16 | 42.64 |
Cash at End of Period | 23.88 | 67.31 | 226.47 | 78.45 | 89.16 |
Diluted Net EPS | -1.96 | -2.25 | -2.07 | -3.36 | NA |
Fiscal Year End for Oric Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -56.97 | -25.01 | -100.70 | -72.37 | -46.89 |
Depreciation/Amortization & Depletion | -3.99 | -1.97 | -5.14 | -3.28 | -1.61 |
Net Change from Assets/Liabilities | -4.80 | -8.17 | 4.90 | 2.91 | -0.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.95 | 4.96 | 15.25 | 11.31 | 7.45 |
Net Cash From Operating Activities | -55.81 | -30.19 | -85.69 | -61.42 | -41.77 |
Property & Equipment | -0.55 | -0.22 | -0.85 | -0.79 | -0.72 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -43.04 | -61.65 | -42.55 | -63.57 | -5.82 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -43.59 | -61.87 | -43.40 | -64.37 | -6.54 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 126.01 | 125.20 | 85.88 | 85.21 | 85.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.17 | -0.17 | -0.23 | 0.00 | 0.00 |
Net Cash from Financing Activities | 125.85 | 125.03 | 85.66 | 85.21 | 85.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 26.45 | 32.98 | -43.43 | -40.58 | 36.87 |
Cash at Beginning of Period | 23.88 | 23.88 | 67.31 | 67.31 | 67.31 |
Cash at End of Period | 50.32 | 56.85 | 23.88 | 26.73 | 104.17 |
Diluted Net EPS | -0.45 | -0.37 | -0.49 | -0.44 | -0.50 |